The third edition of the two-day coastal defence exercise Sea Vigil-22 that concluded on 16 November has seen participation from over 17 government agencies from nine coastal states and four union territories of India.
2-DG s therapeutic use for COVID-19 is set to begin in the coming week. However, there are several gaps in the information surrounding the drug trials and a lack of available data.
Healthcare workers transfer the body of a person who died from COVID-19, at a hospital in Kolkata, May 12, 2021. Photo: Reuters/Rupak De Chowdhuri
Mumbai: On May 1, the Drug Controller General of India (DCGI) approved a drug called 2-deoxy-d-glucose (2-DG) for emergency use among people with moderate and severe COVID-19, to help manage the disease.
This drug was jointly developed by researchers at the Institute of Nuclear Medicine and Allied Sciences, which falls under the Defence Research & Development Organisation (DRDO), and the pharmaceutical giant Dr Reddy’s Laboratories.
In line with the DCGI’s approval for favipiravir, itolizumab and Verafin, the approval for 2-DG is based on poor evidence.